1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide | 212644-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-[6-chloro-2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl)methyl]-4-(dimethylaminosulfonyl)piperazine-2-acetamide
• 英文别名: 2-[1-(6-chloro-2-imidazol-1-ylpyrimidin-4-yl)-4-(dimethylsulfamoyl)piperazin-2-yl]-N-[(3-methoxyphenyl)methyl]acetamide
• CAS: 212644-72-9
• 化学式: C₂₃H₂₉ClN₈O₄S
• 分子量: 549.053
• InChiKey: MYSVBSOFBVOCEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  134
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• N-heterocyclic derivatives as NOS inhibitors
  申请人：Berlex Laboratories, Inc.

  公开号：US20020183323A1

  公开（公告）日：2002-12-05

  N-Heterocyclic derivatives of the formula (I): 1 are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

  本文描述了公式（I）中的N-杂环衍生物1，以及其他N-杂环，作为一氧化氮合酶的抑制剂。本文还描述了含有这些化合物的制药组合物，使用这些化合物作为一氧化氮合酶抑制剂的方法，以及合成这些化合物的过程。
• Novel piperidine derivatives for use in the treatment of chemokine medicated disease states
  申请人：Luckhurst Christopher

  公开号：US20060040984A1

  公开（公告）日：2006-02-23

  The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

  本发明提供了一个公式(I)的化合物：其中变量在此定义；以及制备这种化合物的过程；以及将这种化合物用于治疗趋化因子（例如CCR3）或H1介导的疾病状态的用途。
• Piperidine derivatives for the treatment of chemokine or h1 mediated disease state
  申请人：Luckhurst Christopher

  公开号：US20060281726A1

  公开（公告）日：2006-12-14

  The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

  本发明提供了一种式(I)的化合物，其中变量在此定义；一种制备该化合物的方法；以及使用该化合物治疗趋化因子（如CCR3）或H1介导的疾病状态的方法。
• N-Heterocyclic derivatives as nos inhibitors
  申请人：Berlex, Inc.

  公开号：EP1754703A2

  公开（公告）日：2007-02-21

  N-Heterocyclic derivatives of formula (I) are described herein, as well as other N-Heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

  本文描述了作为一氧化氮合酶抑制剂的式 (I) N-杂环衍生物以及其他 N-杂环。本文还描述了含有这些化合物的药物组合物、使用这些化合物作为一氧化氮合酶抑制剂的方法以及合成这些化合物的工艺。
• Intermediates for the production of pharmaceutically active compounds
  申请人：AstraZeneca AB

  公开号：EP1816123A1

  公开（公告）日：2007-08-08

  The present invention provides a compound of a formula (A), (B) or (C): which is useful for making a compound of formula (I): wherein Z is CO2R3. The compounds of formula (I) are useful in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

  本发明提供了一种式 (A)、(B) 或 (C) 的化合物： 可用于制造式（I）化合物： 其中 Z 为 CO2R3。式（I）化合物可用于治疗趋化因子（如 CCR3）或 H1 介导的疾病状态。